CLINICAL TRIALS PROFILE FOR NORGESTIMATE AND ETHINYL ESTRADIOL
✉ Email this page to a colleague
All Clinical Trials for Norgestimate And Ethinyl Estradiol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00236769 ↗ | A Study of Efficacy and Safety With the Transdermal Contraceptive System. | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 1997-11-01 | The purpose of the study is to evaluate the contraceptive efficacy, safety, cycle control, and compliance with the transdermal contraceptive system. |
| NCT00254865 ↗ | A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 1 | 2002-08-01 | The objective of this study is to compare the levels of the hormones norelgestromin, norgestrel, and ethinyl estradiol in the bloodstream of healthy female volunteers administered ORTHO EVRA® (a transdermal contraceptive patch) and CILEST® (an oral contraceptive). The open-label treatment phase of the study consists of two 28-day cycles of one treatment, a washout period of 28 days, and crossover to two 28-day cycles of the other treatment. |
| NCT00301587 ↗ | A Study to Evaluate Folate Levels in Women Taking Oral Contraceptives | Withdrawn | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 | 1969-12-31 | The purpose of this study is to compare red blood cell folate levels in women who are taking oral contraceptives with or without folic acid |
| NCT00320567 ↗ | The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa | Completed | McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | Phase 2 | 1969-12-31 | The purpose of this study is to evaluate the effect of norgestimate/ethinyl estradiol on lumbar spine (L1-L4) and total hip bone mineral density (BMD) in pediatric subjects with anorexia nervosa. |
| NCT00331071 ↗ | Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks | Completed | Boston Collaborative Drug Surveillance Program | 2002-04-01 | The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with 35 mcg ethinyl estradiol with special attention to duration of use. The study uses data from the PharMetrics Patient-Centric Database and MarketScan database, which are US medical claims databases. | |
| NCT00331071 ↗ | Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks | Completed | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2002-04-01 | The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with 35 mcg ethinyl estradiol with special attention to duration of use. The study uses data from the PharMetrics Patient-Centric Database and MarketScan database, which are US medical claims databases. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Norgestimate And Ethinyl Estradiol
Condition Name
Clinical Trial Locations for Norgestimate And Ethinyl Estradiol
Trials by Country
Clinical Trial Progress for Norgestimate And Ethinyl Estradiol
Clinical Trial Phase
Clinical Trial Sponsors for Norgestimate And Ethinyl Estradiol
Sponsor Name
| Sponsor Name for Norgestimate And Ethinyl Estradiol | |
| Sponsor | Trials |
| Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 9 |
| Bristol-Myers Squibb | 5 |
| McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. | 2 |
| [disabled in preview] | 5 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
